Obiltoxaximab

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameObiltoxaximab
Drug Alias Name奥必托昔单抗奥托萨昔单抗AnthimObiltoxaximab SFLETI-204
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAntrax lethal toxin inhibitors
TargetsAntrax lethal toxin
Therapy Area/IndicationsInhalational anthraxAnthrax
Global Approved IndicationsAnthrax
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2016/03/18
Country/TerritoryUnited StatesEU
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesElusys Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesElusys Therapeutics Inc
Inactive CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)SFL Pharmaceuticals Deutschland GmbH
Active IndicationsAnthrax
Inactive IndicationsInhalational anthrax

Other Information

ATC CodeJ06BB22
Related LinksWikipediaDrugBankKEGG